|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation and amortization | |||||
| Stockbased compensation | |||||
| Issuance of common stock to consultants | |||||
| Foreign currency loss (gain) | |||||
| Changes in operating assets and liabilities: | |||||
| Prepaid expenses and other current and noncurrent assets | |||||
| Accounts payable | |||||
| Accrued expenses | |||||
| Deferred grant revenue | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities: | |||||
| Purchases of property and equipment | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities: | |||||
| Proceeds from the exercise of warrants | |||||
| Proceeds from issuance of common stock | |||||
| Common stock issuance costs | |||||
| Net cash provided by financing activities | |||||
| Change in cash, cash equivalents and restricted cash | |||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | |||||
| Cash, cash equivalents and restricted cash-beginning of year | |||||
| Cash, cash equivalents and restricted cash-end of period | |||||
| Non-cash investing and financing activities: | |||||
| Conversion of Series A convertible preferred stock to common stock | |||||
| Reconciliation of cash, cash equivalents and restricted cash | |||||
| Cash and cash equivalents | |||||
| Restricted cash | |||||
Loading...